Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ice, I agree. FDA approval would/should get the show back on the road.
However your mantra of FDA approval being the only thing that matters to you is not the point. (I think you know that too, but for reasons I don't know but can only guess at, you refuse to engage with. Maybe the hole you have dug is to deep to climb out of...)
Anyway, say a bid goes in tomorrow at 90p and settles around there or even up to 200p, pick a (reasonable) number, way ahead of any potential FDA. Takes all the risk away for shareholders on timings, of approvals, future trials, of cash runway etc etc. For a lot of people they will multi bag. I think that would go through.
There will have been a huge churn in this stock over the last few years, with some banking profit on the way down, but many more cutting their losses. The more you have new(er) shareholders, the more likely they are to have bought in lower down and will see almost any offer price as a profit. (And may be less emotionally tied to the stock as that bond usually develops and strengthens over time)
I don't know what the breakdown is but the PI base might not be as hell bent as you are on seeing it to your conclusion.
So your view of FDA approval that answers and solves all problems may never come to pass.
That's why the SP matters at all times, that's why buying in at the right time matters. Your at best simplistic, one option, view that the world will work to your time table is a pretty risky strategy. (Holding that view for 5 minutes or 5 years does not decrease the risk, by the way).
My mantra here has long been "its not about the science, its about the money" was to engender conversation given what AVCT are trying to do, but truly, its only ever about the money.
PI's are just fodder for these companies to keep the lights on. Its not about us, its about the big players. AS could approve a buy out at 130p, and get a new fantastic pay plan and options with the new owner. Why would he care? Whatever happens if the tech is successful he will become immensely rich. The PI may or may not, but for sure, we are not part of the equation. We may get lucky, who knows, but that's what it will be.
Stodgy for cfo, you’ve got my 10 votes
I want smith and Gardner out .
Agree ,all three must go.
Oh, he’s lovely. I found it charming when he described PIs as liquidity. That’s his view of the majority owners of his business. That’s plenty ammunition to call for his head. It’s obvious his goals aren’t fully aligned. As long as he’s banking his whopper of a salary and his mate Tony is chucking options his way, then all is rosy from his perspective.
I’d like to see him stripped of all options. If he wants some back then he can cash them in at £50. Keep him in a cupboard as a board advisor if you must but get the naive buffoon away from decision making and spouting vacuous superlatives and pathetically inaccurate timelines.
Now for a bit of balance, he’s got AVA6k in the clinic. He was opportunistic in the covid raise to achieve that. Frustrating at the time but the right thing. Congrats. I can’t say the latest raise was the right thing - he left it to the last minute and over looked available retail cash previously - because we’re just here for exit liquidity. My 70p top up could have been at over a quid straight in their bank account, but he preferred 50p from funds that will make their cash and be gone within a year.
In the same way that others have moved on as the company has matured, it’s now his turn. Thanks Alan, best of luck for the future.
Thanks DTW. I’m looking forward not back, therefore is the question do we have a commercial team in place to maximise value for shareholders? I would like to add if we are genuinely standing on the verge of a potential paradigm shift in the treatment of many cancers from the moral standpoint do we have the deal making team in place to ensure multiple deals are agreed with big pharma to ensure as many treatments as possible can be made available to as many patients as possible as quickly as possible. The answer simply is what team? If Alastair was lacking in commercial experience then he could have built a comprehensive and experienced team around him. I believe we are talking about deals eventually worth billions of dollars. Given the data is providing proof of concept we need an experienced ceo and board who can work together to build the experienced commercial teams required. That is why I believe we need the change that I am told will happen next week.
Good post Soleboy
Have to admit I'm torn regarding AS. On one hand, the AACR P1a/Q&A update was incredibly positive. The trial has undoubtedly been handled well and the latent value of the PRE/Cision platform is obvious for all to see. AS could be forgiven for believing that under his stewardship he has added significant value that will soon be realised.
On the other hand, are we judging AS simply on the SP? It is a key measure for sure but in the absence of a detailed explanation, we are left to assume that all the recent fundraising has been handled badly. Consensus amongst SH's clearly believes this to be true, however, we don't know the caveats imposed by Heights or the conditions imposed around the 50p raise. Would other AIM CEO's desperate for cash be looking enviously at AVCT? even at 50p?
Perhaps it is an unrealistic request but if the Co were equally willing to explain commercial strategy/fund raising as they are to explain scientific progress then this would perhaps go some way to allaying shareholder concerns and cool the social media rumour mill.
AS could be forgiven for feeling defensive and challenging SH's that whilst the SP is currently in the toilet, he has delivered on arguably far more important metrics. Fantastic trial progress, fully funded for at least 2 years, all IP assets 100% retained, two key appointments recently made to take the Co forward into the commercial phase.
In the hypothetical scenario that we were today sitting at ATH's, I would suggest that very few LTH's would be selling because they would fully understand that the potential for a BP takeout would be well in excess of ATH's and this only increases as the data accumulates .
Having said all that, I have to agree that the time for no questions asked, big salaries, option packages, first class tickets to London etc can no longer be funded by shareholders, the BOD has to start paying its own way and all remuneration as we enter the commercial phase has to be linked to Co performance and the SP.
I want smith and Gardner out .
Smith overpromises then shafts you
Gardner can’t even add up
“Jesus I am in a comedy club. here are a few more for you Ice. "Dont worry about funding", "Shareholder Value", "No Placing" "Raise unlikely at under £1" "Start of the value curve" "Start of commercialisation" "Lots want it" "Prefer non dilutive methods" "We dont know how to use a calulator but please take us seriously" "I have a lot riding on avacta as I have a lot of options (Plus my small 400k salary)"
What’s the above got to do with making cash on FDA approval of AVA6000. Making changes this late in the game won’t help anything.
"𝗘𝗦𝗖𝗠𝗜𝗗 𝟮𝟬𝟮𝟰 has started!
Interested in learning more about rapid tests? Or exploring potential partnerships?
Come and meet Sébastien (COO) and Audrey (Marketing manager) at booth F-10 ! Looking forward to meeting you!
#ESCMID2024 #AntiMicrobialResistance #MedicalBiotechnology #RapidDiagnostics #HealthcareInnovation"
https://www.linkedin.com/feed/update/urn:li:activity:7189928704683204608/
CFO is the position in which I would like to see a change occur.
Good, balanced post SoleBoy.
AS seems like a genuine, decent bloke but the disastrous raise has cost shareholders a lot of money. And the “optionality” and don’t worry about funding comment will haunt him forever. Many, including me, took those words at face value.
If he does go it will be a sad ending. But he has been well remunerated and has a shed load of options.
I don’t think he has the deal making experience to take us to the next commercial stage.
"Who says they are mistakes"
Jesus I am in a comedy club. here are a few more for you Ice. "Dont worry about funding", "Shareholder Value", "No Placing" "Raise unlikely at under £1" "Start of the value curve" "Start of commercialisation" "Lots want it" "Prefer non dilutive methods" "We dont know how to use a calulator but please take us seriously" "I have a lot riding on avacta as I have a lot of options (Plus my small 400k salary)"
As always no doubt in the science or the fact that AS is a great scientist regardless of what I think of him as a CEO its the reason I have not sold but the management team seems to be serverely lacking in my opinion but once again lets pretend everything is A OK and there does not need to be any accountability. Id like to start with why the feck our CFO either cant use a calculator or they are so disorganisaed they dont double check a RNS, pretty much everyone spotted that mistake as soon as they read it how did a company valued at 150m not? Rookie mistake, who is to say the next one is not the CFO signing away the company for £1.00 a share instead of £10.00 because he didnt count his zeros)
I would love AS and the team to prove me wrong and see true value for the company and make me eat my words as it would make me a very rich fella but I just dont see it under this leadership after 4 years and a lot of fluff.
Great post Soleboy
Start of Pre/Cision trial
Smith, Bell ,McClaughlin.
Didn’t see any mistakes through trial everything went well,but it’s now
Smith, Coughlin,Bennett
All this change at the top will affect SP and damage the company?
SP held up when Bell ,McClaughlin were dropped in one liners in RNS’s
Only damage has been car crash placing last few months.
Out the 5 of them only Smith keeps over promising.
Gardiner sitting in the background giving himself shares.
Let’s see what happens next week.
I’m hoping side ways move for Smith and Gardiner moved to Man City accounting team were he would fit in.
I will definitely still be here. I make medium / long term investments so no interest in exiting before commercialisation or buy out.
Ooo love a rumour, Fiona in charge though her presentation skills are pretty boring to be honest.
So Tuesday is MASSIVE, shorters will burn. Can't wait, I don't think it can be built up too much. Whoop whoop.
Who says they are mistakes, short term share price fluctuations has no impact on the company being successful and making good longterm strategic decisions for the overall benefit of the investors. We will ultimately see how this plays out I will be here not sure you will be. 😉😝
You keep happy clapping Ice. I’m happy with my investment here and have doubled my position in the last few weeks. It’ll undoubtedly come good but there need to be accountability for recent mistakes.
It is of course all personal opinion which makes a chat board worthwhile. Firstly next week is not an AGM that’s in Summer. Secondly I am a percentage holder, least I was 😂 so after 14 years am very much looking at the bigger picture. I believe Alastair to be a man of genuine integrity and can only praise the tech he has acquired for Avacta. But and it is a very large BUT commercialism has not followed on any front. We were promised commercial turning points in 2015 / 2016/ 2017 with various diagnostics, then Affimers, then TMAC, then Covid LFD now pre|CISION. I think in deference to Alastair and his character long term shareholders have given him every latitude. The last few months have, as they say, been just been the final straw that broke the camels back.
As to senior staff rotation / loss. It is often not a good thing but if you think about it that’s exactly what we’ve had under Alastair’s tenure. The CFO is one of the only one’s to survive and I certainly have a view on that.
Discussion boards are for discussion and exchange of knowledge. I hope this thread promotes discussion of different points of view. Sensible views are all valid.
Haha rose tinted glasses you require spec savers you are so short sighted it is unbelievable. At the end of the day all that matters is funding and FDA approval. The science strongly suggests we will get FDA approval. On FDA approval even if we did another 50% Dilution the company would still be valued in the Billions based on validation of drug and platform. Approved Oncology drugs are worth some serious cash who would have thought. Not rose tinted glasses just good old logical conclusions if the trial is successful which the data suggests it will be.
Sadly not. Think we’ll have to wait for that. Although it does raise an interesting question. If AS is no longer CEO, will the focus change from asset retention towards licensing and or TO?
Are you for real or are those rose tinted glasses welded to your face ? I suppose you’d be happy if he made that statement again then did a raise at 25p.
Well we don’t??? We are fully funded for the next 2 years.
Did they also mention the 10Bn takeover or is that the week after next?
Have you forgotten “funding - you don’t need to worry about that” - a statement that has proved to be very foolish indeed.
The results have been exceptional throughout the trial but that still hasn’t stopped the decimation of the SP - who needs to shoulder the blame for that ? You can’t ignore the fact that major errors in judgment have been made and that can’t be ignored.